Pfizer’s $15 Billion War Chest: What Will They Buy After the Danuglipron Failure? 

Pfizer recently reported its first-quarter 2025 financial results, providing an overall positive snapshot of its performance within a challenging market environment. Revenue was reported at $13.7 billion, marking a 6% operational decline largely driven by lower Paxlovid sales, partly reflecting a one-time Paxlovid revenue credit from the prior year. Despite this, some of its core products such as the Vyndaqel family, Nurtec, and Padcev demonstrated strong growth, reinforcing the company’s focus on prioritizing key growth drivers. Additionally, Pfizer’s management highlighted robust operating margin performance and effective cost management strategies, suggesting operational resilience.